ProCE Banner Activity

CE / CME

Incorporating Opioid Use Disorder Screening and Treatment into HIV and HCV Management

In this interactive video module, CCO’s expert faculty provide insights on the critical role ID specialists and hepatologists can play in addressing the ongoing opioid use disorder (OUD) epidemic and discuss useful strategies for incorporating OUD screening, patient evaluation, and treatment into HIV/HCV care settings.

Pharmacists: 1.75 contact hours (0.175 CEUs)

Physicians: Maximum of 1.75 AMA PRA Category 1 Credits

Nurses: 1.75 Nursing contact hours

Released: February 06, 2020

Expiration: February 05, 2021

No longer available for credit.

Share

Faculty

Sandra Springer

Sandra Springer, MD

Associate Professor of Medicine
Division of Infectious Disease
Department of Internal Medicine
Yale School of Medicine
New Haven, Connecticut
Attending Physician
Section of Infectious Disease
Department of Internal
Medicine
Veterans Administration Connecticut Healthcare Services
West Haven, Connecticut

Christian B. Ramers

Christian B. Ramers, MD, MPH

Associate Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Chief, Population Health
Director, Graduate Medical Education
Family Health Centers of San Diego
San Diego, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead

Partners

ASAM

ProCE Banner

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients with opioid addiction and HCV and/or HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Provide appropriate counsel to patients with opioid use disorder on how medication treatment for opioid use disorder affects health outcomes in patients living with HCV and/or HIV infection
  • Distinguish between key characteristics of FDA-approved medications for treating opioid use disorder when considering the most appropriate option for each patient
  • Implement strategies to effectively comanage substance use disorder with HCV and/or HIV infection

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Sandra Springer, MD

Associate Professor of Medicine
Division of Infectious Disease
Department of Internal Medicine
Yale School of Medicine
New Haven, Connecticut
Attending Physician
Section of Infectious Disease
Department of Internal
Medicine
Veterans Administration Connecticut Healthcare Services
West Haven, Connecticut

Sandra Springer, MD, has disclosed that she has received consulting fees from Alkermes Inc. and DKB Med and fees for non-CME/CE services from DKB Med.

Faculty Disclosure

Primary Author

Christian B. Ramers, MD, MPH

Associate Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Chief, Population Health
Director, Graduate Medical Education
Family Health Centers of San Diego
San Diego, California

Christian B. Ramers, MD, MPH, has disclosed that he has received fees for non-CME/CE services from AbbVie, Gilead Sciences, Merck, and ViiV Healthcare; consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; and funds for research support from AbbVie and Gilead Sciences.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra D. Cravens, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.75 contact hour.

Credit Designation

CCO designates this continuing education activity for 1.75 contact hour (0.175 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-023-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 06, 2020, through February 05, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in achieving key clinical outcomes of diagnosis, linkage to care, and successful treatment in patients with opioid addiction and HCV and/or HIV infection.